Advances in chemotherapy of non-small cell lung cancer

Chest

Volumn 130, Issue 4, 2006, Pages 1211-1219

  Molina, Julian R ^a,b   Adjei, Alex A ^a   Jett, James R ^a  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Chemotherapy; Lung cancer; Targeted therapy

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; UFT; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VATALANIB; VINBLASTINE; VINCRISTINE; VINDESINE;

ADJUVANT CHEMOTHERAPY; BLEEDING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HEMOPTYSIS; HUMAN; HYPERTENSION; LUNG CANCER; LUNG NON SMALL CELL CANCER; META ANALYSIS; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNITED STATES;

EID: 33750069402     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.4.1211     Document Type: Article

References (53)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30
2. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: updated 2003. J Clin Oncol 2004; 22:330-353
3. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC# 704865) in patients with advanced non-squamous, non-small-cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial E4599 [abstract]. J Clin Oncol 2005; 23:2s
4. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311:899-909
5. Scagliotti GV, Fossati R, Torn V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small cell lung cancer. J Natl Cancer Inst 2003; 95:1453-1461
6. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004; 26:173-182
7. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351-360
8. Winton TL, Livingston R, Johnson D, et al. Vinorelbine and cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352:2589-2597
9. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (SCLC): update of Cancer and Leukemia Group B (CALGB) Protocol 9633 [abstract]. Proc Am Soc Clin Oncol 2006; 24:365
10. Douillard J, Rosell R, Delena M, et al. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts); final results after 70-month median follow-up [abstract]. Proc Am Soc Clin Oncol 2005; 24:619
11. Xu G, Rong T, Lin P. Adjuvant chemotherapy following radical surgery for non-small cell lung cancer: a randomized study on 70 patients. Chin Med J (Engl) 2000; 113:617-620
12. Mineo TC, Ambrogi V, Corsaro V, et al. Postoperative adjuvant therapy for stage IB non-small cell lung cancer. Eur J Cardiothorac Surg 2001; 20:378-384
13. Nakagawa M, Tanaka F, Tsubota N, et al. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG); the 4th study. Ann Oncol 2005; 16:75-80
14. Tada H, Tsuchiya R, Ichinose Y, et al. Randomized study of ,adjuvant chemotherapy for completely resected non-small cell lung cancer: lack of prognostic significance in DNA ploidy pattern at adjuvant setting [abstract]. Proc Am Soc Clin Oncol 2002; 21:313
15. Endo C, Saito Y, Iwanami H, et al. A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: north-east Japan Study Group for Lung Cancer Surgery. Lung Cancer 2003; 40:181-186
16. Imaizumi M. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer. Lung Cancer 2005; 49:85-94
17. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with Uracil-Tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350:1713-1721
18. Tada H, Tsuchiya R, Ichinose Y, et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer 2004; 43:167-173
19. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17:2692-2699
20. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410 [abstract]. Proc Am Soc Clin Oncol 2004; 22:621
21. Fisher MD, D'Orazio A. Concurrent chemoradiotherapy followed by consolidation docetaxel in stage IIIB non small-cell lung cancer (SWOG 9504). Clin Lung Cancer 2000; 1:25-26
22. Vokes EE, Herdon JE, Keley MJ, et al. Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): initial analysis of a randomized phase III trial [abstract]. Proc Am Soc Clin Oncol 2004; 22:618
23. Barlesi F, Pujol JL, Daures JP. Should chemotherapy (Cx) for advanced non-small cell lung cancer (NSCLC) be platinum-based? A literature-based meta-analysis of randomized trials. J Clin Oncol 2005; 24:673s
24. D'Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005; 23:2926-2936
25. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98
26. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210-3218
27. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20:4285-4291
28. Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2005; 23:2937-2945
29. Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005; 16:602-610
30. Kosmidis PA, Kalofonos C, Syrigos K, et al. Paclitaxel and gemcitabine vs. carboplatin and gemcitabine: a multicenter phase III randomized trial in patients with advanced inoperable non-small cell lung cancer (NSCLC). J Clin Oncol 2005; 23:621s
31. Treat J, Belani CP, Edelman MJ, et al. A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC): update of Alpha Oncology trial (A1-99002L). J Clin Oncol 2005; 23:627s
32. Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEM-VIN investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21:3025-3034
33. D'Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005; 23:2926-2936
34. American Society of Clinical Oncology. Treatment of unresectable non-small-cell lung cancer guideline: update 2003; adopted on September 8, 2003, by the American Society of Clinical Oncology. J Clin Oncol 2004; 22:330-353
35. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-2799
36. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158
37. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21:2237-2246
38. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158
39. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo controlled, multicenter study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-1537
40. Kelly K, Gaspar L, Chansky K, et al. Low incidence of pneumonitis on SWOG 0023: a preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2005; 23:7058
41. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22:3238-3247
42. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure on 1st line or 2nd line chemotherapy: a National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial [abstract]. J Clin Oncol 2004; 22:622s
43. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract] J Clin Oncol 2004; 22:619s
44. Herbst RS, Prager D, Hermann R, et al. TRIBUTE-A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2004; 22:619s
45. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500
46. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139
47. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306-13311
48. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305:1163-1167
49. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-2191
50. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21:3016-3024
51. Kubota K, Watanabe K, Kunitoh H, et al. Phase II randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004; 22:254-261
52. Cardenal F, López-Cabrerizo MP, Antón A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999; 17:12-18
53. Kubota K, Nishiwaki Y, Ohashi Y, et al. The Four-Arm Cooperative Study (FACS) for advanced non-small-cell lung cancer (NSCLC) [editorial]. J Clin Oncol 2004; 22:14s